Top Page
Skin Elements Limited
(Sydney:SKN)
Skin Elements Limited (SKN) vs. iShares MSCI Australia ETF (EWA)
Skin Elements Limited Business Overview & Revenue Model
Skin Elements Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 469.96K | 469.96K | 416.20K | 194.13K | 1.41M | 288.74K |
| Gross Profit | 406.29K | 406.29K | 361.87K | -204.55K | 742.98K | -213.47K |
| EBITDA | -1.63M | -1.63M | -2.08M | -12.08M | -2.15M | -3.54M |
| Net Income | -1.73M | -1.73M | -2.16M | -11.42M | -1.58M | -3.04M |
Balance Sheet | ||||||
| Total Assets | 720.21K | 720.21K | 1.44M | 1.69M | 11.10M | 11.03M |
| Cash, Cash Equivalents and Short-Term Investments | 59.65K | 59.65K | 115.07K | 358.43K | 748.05K | 287.63K |
| Total Debt | 444.39K | 444.39K | 731.73K | 17.75K | 24.53K | 30.99K |
| Total Liabilities | 2.66M | 2.66M | 3.08M | 1.08M | 1.05M | 1.42M |
| Stockholders Equity | -1.94M | -1.94M | -1.63M | 604.80K | 10.05M | 9.60M |
Cash Flow | ||||||
| Free Cash Flow | 233.85K | 233.85K | -279.38K | -1.84M | -1.50M | -2.74M |
| Operating Cash Flow | 233.85K | 233.85K | -279.38K | -1.84M | -1.50M | -2.70M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -36.41K |
| Financing Cash Flow | -289.27K | -289.27K | 36.02K | 1.45M | 1.96M | 2.82M |
Skin Elements Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$35.78M | 6.68 | 14.70% | 1.54% | 6.89% | 607.27% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$28.03M | -6.93 | -77.92% | ― | 17.41% | 67.94% | |
45 Neutral | AU$15.00M | ― | ― | ― | 12.92% | 34.21% | |
43 Neutral | AU$7.33M | -0.67 | ― | ― | -21.84% | 79.99% | |
38 Underperform | AU$2.33M | -0.49 | -115.03% | ― | 24.70% | -312.00% |
Skin Elements Limited Corporate Events
Skin Elements Limited has expanded its share capital through the allotment of 75 million fully paid ordinary shares to a lead manager and the issue of a further 125 million shares upon conversion of unquoted options exercisable at $0.006, ahead of their 2028 expiry. The company has confirmed that these shares were issued without a disclosure document under the Corporations Act but stated it remains compliant with its continuous disclosure and financial reporting obligations, and that there is no excluded information requiring disclosure, signalling a routine capital management step intended to support ongoing operations without indicating any undisclosed material developments for investors.
Skin Elements Limited has disclosed changes in the indirect equity interests held by director Peter Malone through his associated entities. The notice details the conversion of 119,025,000 options into ordinary shares via Empire Services (AUST) Pty Ltd and an internal transfer of 163,050,000 ordinary shares to Josaxa Pty Ltd
Skin Elements Limited has applied to the ASX for quotation of 125 million new fully paid ordinary shares, issued on 17 December 2025. The substantial increase in quoted securities expands the company’s share base and may provide additional capital or facilitate conversions of existing instruments, with potential implications for shareholder dilution and the company’s positioning in public markets.
Skin Elements Limited has notified the market of the issue of 125 million new fully paid ordinary shares following the exercise or conversion of previously unquoted options or convertible securities. The substantial increase in the company’s issued capital, effective 17 December 2025, signals a significant capital-raising or balance-sheet event that will dilute existing shareholders but may provide additional funding capacity to support future operational or strategic initiatives.
Skin Elements Limited has disclosed a substantial change in the holdings of director Peter Malone, reported as an indirect interest via several trustee and beneficiary structures. The filing details the issue of 400 million new ordinary shares at a deemed price of $0.002 per share in lieu of unpaid director fees, along with 200 million options exercisable at $0.006 expiring in December 2028, significantly increasing Malone’s equity and option exposure in the company and signalling both ongoing director support and notable dilution for existing shareholders.
Skin Elements Limited has disclosed the issue of 37.5 million unquoted options, exercisable at $0.006 and expiring on 12 December 2028, as part of its latest capital-related corporate actions. The move increases the company’s pool of equity-linked securities and may signal efforts to incentivise stakeholders or support future funding flexibility, though no additional operational or strategic context was provided in the announcement.
Skin Elements Limited has applied to the ASX for quotation of 75 million new ordinary fully paid shares, issued on 18 December 2025 as Lead Manager shares under shareholder approval granted on 28 November 2025. The move will expand the company’s quoted securities base and reflects capital management activities aimed at supporting its operations and market presence, with implications for existing shareholders through increased share supply and potential dilution.
Skin Elements Limited has completed the allotment of 1,092,500,000 fully paid ordinary shares as part of a two-tranche placement, with an additional 500,000,000 shares allotted to a director and senior executive following shareholder approval. This strategic move, managed by 62 Capital Pty Ltd, is expected to bolster the company’s capital structure, potentially enhancing its market position and operational capabilities in the biotechnology sector.
Skin Elements Limited announced the issuance of 250 million unquoted equity securities in the form of options exercisable at $0.006, set to expire on December 12, 2028. This strategic move could potentially enhance the company’s capital structure and provide additional financial resources for its operations, impacting its market positioning and offering potential benefits to stakeholders.
Skin Elements Limited announced the approval and upcoming quotation of 500,000,000 ordinary fully paid securities on the ASX, following shareholder approval received on November 28, 2025. This move is expected to enhance the company’s capital structure and potentially strengthen its market position by providing additional resources for growth and development.
Skin Elements Limited has announced the issuance of 625,000,000 unquoted equity securities, specifically options exercisable at $0.006 and expiring on December 12, 2028. This move is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
Skin Elements Limited has announced the quotation of 1,092,500,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective December 12, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s financial flexibility and visibility in the market.
Skin Elements Limited has successfully completed a $2.5 million placement to fund the commercialization of its ECO Nurture bio-stimulant, aimed at protecting kiwifruit orchards in New Zealand. This strategic move positions the company to offer a sustainable alternative to chemical-based sprays, leveraging the proven efficacy of ECO Nurture and marking a significant market opportunity for the company’s expansion.
Skin Elements Limited has announced its 2025 Annual General Meeting, scheduled for November 28, 2025, in West Perth, Australia. The company is adapting to the Corporations Amendments Act 2022 by providing electronic access to the Notice of Meeting, encouraging shareholders to vote online or via proxy. This move reflects a shift towards digital engagement and compliance with modern corporate governance practices, potentially enhancing shareholder participation and operational efficiency.
Skin Elements Limited has completed the allotment of 157,500,000 fully paid ordinary shares as part of a two-tranche placement with 62 Capital Pty Ltd as the lead manager. This move, announced on 15 October 2025, signifies the company’s strategic efforts to strengthen its capital base, potentially enhancing its market position and operational capabilities in the biotechnology sector.
Skin Elements Limited has announced the quotation of 157,500,000 ordinary fully paid securities on the Australian Securities Exchange. This move is part of previously announced transactions and could potentially enhance the company’s market presence and liquidity, benefiting stakeholders and investors.
Skin Elements Limited announced a proposed issue of securities, with plans to issue 37.5 million options exercisable at $0.006 and 75 million fully paid ordinary shares. This move is expected to enhance the company’s capital base, potentially supporting its growth initiatives and strengthening its position in the competitive skincare industry.
Skin Elements Limited has announced a proposed issuance of securities, including 625,000,000 options and 1,092,500,000 fully paid ordinary shares, with a planned issue date of December 1, 2025. This move is likely to impact the company’s financial structure and market positioning, potentially enhancing its capital base and providing funds for future growth initiatives.
Skin Elements Limited has announced a proposed issue of 157,500,000 fully paid ordinary securities, scheduled for issuance on October 20, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market positioning by enhancing its financial resources for growth and development, which could have implications for stakeholders and investors.
Skin Elements Limited has secured $2.5 million through a two-tranche placement at $0.002 per share, with additional options, to fund the commercialization of its SE Formula biotechnology. This capital injection, managed by 62 Capital Pty Ltd, will support the company’s transition into commercial revenue programs, although it will result in a 64% dilution of current shareholders’ holdings.